Pfizer Sees Ophthalmology Opportunity With NicOx’ Nitric Oxide-Donating Compound
This article was originally published in The Pink Sheet Daily
Pfizer will pay NicOx a total of €37 mil. if the compound becomes a commercialized product.
You may also be interested in...
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.